Cenobamate is a newly-FDA and EMA approved drug used to treat -focal-onset seizures in adult patients. The aim of the current study is to analyse retrospectively the overall effectiveness and tolerability of cenobamate from real-world data collected in patients who partecipated in the Early Access Program (EAP) and were treated with cenobamate as adjunctive ASM.
Cenobamate is a new approved drug used to treat -focal-onset seizures in adult patients. This novel tetrazole-derived carbamate seems to act primarily by two mechanisms that are commonly associated with epilepsy: cenobamate acts as a positive allosteric modulator of the GABAA ion channels and is effective in reducing repetitive neuronal firing by inhibition of voltage-gated sodium channels, although the complete mechanism of action is currently unknown. In clinical trials, cenobamate showed also low toxicity and adverse drug reaction profile. In European Union (EU), cenobamate received the marketing authorisation, valid throughout the EU, in March 2021. Starting from September 2020 an EAP was initiated with cenobamate as adjunctive ASM in several EU Countries such as Germany, France, and UK. Real-world data are of importance to understand and confirm the efficacy and safety profile of drugs outside of the clinical trial setting. The aim of the current study is to analyse the overall effectiveness and tolerability of cenobamate from real-world data in a large series of patients treated with cenobamate as adjunctive ASM. As a consequence, a retrospective collection and analysis of the data of the patients who participated in the EAP, according to the authorization received from the local regulatory or ethic authorities, was conducted.
Study Type
OBSERVATIONAL
Enrollment
319
Hôpital Pierre Wertheimer - Hopsices Civils de Lyon
Bron, France
CHRU de Lille - Hôpital Roger Salengro (LILLE)
Lille, France
Centre Hospitalier Universitaire (CHU) de Marseille - Hopital de la Timone
Marseille, France
CHRU de Nancy -Hopital Central, Service de Neurologie
Nancy, France
Hôpital de la Pitié-Salpêtrière
Paris, France
CHU Rennes - Pontchaillou Hospital
Rennes, France
CHU de Rouen Hôpital Charles-NicolleService de Neurophysiologie
Rouen, France
CHU de Strasbourg - Hôpital de Hautepierre
Strasbourg, France
Epilepsieklinik Tabor
Bernau bei Berlin, Germany
Epilepsy Center Bethel hospital Mara
Bielefeld, Germany
...and 13 more locations
Responder rate (%) at 3 months from the start of maintenance
Percentage of responder rate (defined as a ≥50% reduction from screening/baseline in focal onset seizure frequency) after 3 months of maintenance phase.
Time frame: 3 months from the start of maintenance
Portion of responders
Portion of responders (defined as a ≥50% and \<100% reduction from screening/baseline in focal onset seizure frequency) at 1 and 3 months after start of cenobamate therapy
Time frame: 1 and 3 months after start of cenobamate therapy
Portion of responders
Portion of responders (defined as a ≥50% and \<100% reduction from screening/baseline in focal onset seizure frequency) at 3, 6 and 12 months after the completion of the titration and its relation with the dosage.
Time frame: 3, 6 and 12 months after the completion of the titration and its relation with the dosage.
Portion of seizure free
Portion of seizure free (100% reduction from screening/baseline) 1 and 3 months after start of cenobamate therapy
Time frame: 1 and 3 months after start of cenobamate therapy
Portion of seizure free
Portion of seizure free (100% reduction from screening/baseline)3, 6 and 12 months after the completion of the titration and its relation with the dosage.
Time frame: 3, 6 and 12 months after the completion of the titration and its relation with the dosage.
Retention rate
Retention rate measured as percentage of patients remaining in the study and on adjunctive therapy at: 1 and 3 months after start of cenobamate therapy
Time frame: 1 and 3 months after start of cenobamate therapy
Retention rate
Retention rate measured as percentage of patients remaining in the study and on adjunctive therapy at 3, 6 and 12 months after the completion of the titration and its relation with the dosage.
Time frame: 3, 6 and 12 months after the completion of the titration
No. of Adverse Reactions (ADRs),
Adverse Reactions (ADRs), including DRESS, rash/hypersensitivity occurred during the EAP.
Time frame: Through study completion, an average of 2 years
Change in Seizures Frequency
Change in Seizures Frequency at 1 and 3 months after start of cenobamate therapy,
Time frame: 1 and 3 months after start of cenobamate therapy
Change in Seizures Frequency
Change in Seizures Frequency at 3, 6 and 12 months after the completion of the titration
Time frame: 3, 6 and 12 months after the completion of the titration
Assessment of quality of life
The quality of life was assessed through the Questionnaire Quality of Life in Epilepsy Inventory - 31 items
Time frame: 1 and 3 months after start of cenobamate therapy
Assessment of quality of life
The quality of life was assessed through the Questionnaire Quality of Life in Epilepsy Inventory - 31 items
Time frame: 3, 6 and 12 months after the completion of the titration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.